Meet MSK Kids Pediatric Neuro-Oncologist Matthias Karajannis
Matthias A. Karajannis, MD, MS
Chief, Pediatric Neuro-Oncology Service
Brain and Spinal Cord Tumors; Peripheral Nerve Sheath Tumors; Langerhans Cell Histiocytosis, Neurofibromatosis
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Karajannis accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MS, New York University School of Medicine; MD, Free University Berlin
Pediatrics – Duke University Medical Center
Pediatric Hematology/Oncology – Memorial Sloan Kettering Cancer Center; Pediatric Neuro-Oncology – Memorial Sloan Kettering Cancer Center
General Pediatrics; Pediatric Hematology/Oncology
I am a pediatric neuro-oncologist who cares for children with brain tumors, spinal cord tumors, and neurofibromatosis, as I have for the past two decades. As Chief of the Pediatric Neuro-Oncology Service at Memorial Sloan Kettering, I feel privileged to be part of a community of some of the most dedicated clinicians and scientists in the world. On the MSK Kids team, we are all committed to our young patients and share a drive to improve their diagnosis and treatment.
I went to medical school during a time when rapid progress was being made to treat children with cancer using chemotherapy, particularly children with leukemia. I witnessed how collaboration, laboratory research, and clinical research turned once-deadly cancers into curable diseases. After completing my pediatric residency training and a fellowship in pediatric hematology/oncology, I decided to pursue additional training in pediatric neuro-oncology. I realized that despite the progress that had been made, many children with brain tumors were not doing well. There is an urgent need for new therapies that are more effective and have fewer side effects.
At MSK, we have the most skilled and experienced medical and surgical experts caring for children with brain tumors. First and foremost, we rely on one another to make the most accurate diagnosis. Because of advances in our understanding of the molecular roots of cancer, we now have the unprecedented ability to distinguish brain tumors that may look alike under the microscope but behave and respond to treatment differently. This enhanced understanding also lets us identify weaknesses in tumors that we can target with special drugs. This approach, called precision medicine, is changing the way we care for children with brain tumors and has tremendous potential.
Once we have learned what kind of tumor a child has, our team of experts — together with our patients and their families — creates a personalized care plan. Some children with low-grade or noncancerous tumors may only need to be watched. Those with more aggressive cancers may need surgery, chemotherapy, radiation therapy, or immunotherapy. All of these treatments are available at MSK. We also have a strong clinical trials program for children with brain tumors. These patients may be able to receive promising new treatments. Our goal for every child is a cure while minimizing the side effects of treatment.
In addition to caring for patients, I conduct research. My research translates clinical observations and findings from the laboratory into better ways to diagnose and treat children and young adults with brain tumors. I am currently the principal investigator of several early-phase clinical trials to find new treatments for people with neurofibromatosis. This inherited condition predisposes people to nervous system tumors. I am also serving in leadership roles and as study chair in multicenter clinical trial groups, such as the Children’s Oncology Group, the Pediatric Brain Tumor Consortium, and the Neurofibromatosis Clinical Trials Consortium.
I recognize that a cancer diagnosis is perhaps the most difficult and challenging time in the life of a child and their family. Each situation is unique. To that end, all patients and families can rest assured that our experts will be with them throughout the entire experience — from diagnosis through treatment and survivorship. We are a team, and we are here to make sure that our patients receive the very best care available.
All patients and families can rest assured that our experts will be with them throughout the entire experience — from diagnosis through treatment and survivorship.
- Clinical Trials Investigated by Dr. Karajannis
- A Phase I/II Study of Alectinib in Children and Adolescents with Solid Tumors or Central Nervous System Tumors Containing a Change in the ALK Gene
- A Phase II Study Assessing the Use of Omburtamab Radioimmunotherapy for Recurrent Medulloblastoma and Ependymoma in Children and Adolescents
- A Phase II Study of Crizotinib for Children and Adults with Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
- Clinical Trials Co-Investigated by Dr. Karajannis
- A Phase I Study of APX005M Immunotherapy in Pediatric Patients with Persistent or Recurrent Brain Tumors and Newly Diagnosed Brain Stem Glioma
- A Phase I/II Study of Selinexor and Radiation Therapy for Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma and High-Grade Glioma
- A Pilot Study of SurVaxM in Children and Young Adults with Progressive or Relapsed Medulloblastoma, High-Grade Glioma, or Ependymoma or Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Visit PubMed for a full listing of Dr. Karajannis’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Matthias A. Karajannis discloses the following relationships and financial interests:
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.